#### Disclaimer

The primary focus of this resource is to be an internal training tool for RTS,S malaria vaccine candidate, containing related data in the format of a Q&A for Medical Affairs personnel. Information presented here is not for external distribution.

Whilst this document can be inspirational for reactive responses to experts or medical enquiries, local regulations, the GSK Code of Practice, scientific engagement principles and/or medical information processes should be followed appropriately.

##### Please Note

* For media enquiries, please refer to the specific reactive Q&A for Media Enquiries and notify the Global Pipeline Communications team before you respond to a request for an interview so that they can help you to prepare (contact person: Aoife Pauley at [aoife.x.pauley@gsk.com](mailto:aoife.x.pauley@gsk.com)).
* The vaccine RTS,S/AS01 has completed phase 3 clinical program and positive regulatory assessment from the European Medicines Agency, but is not yet authorized for marketing in any country. The RTS,S vaccine is being developed in Public Private Partnership with PATH-MVI, as an additional tool to be added to the currently available malaria preventive interventions and for implementation through the national immunization programs in malaria endemic regions in sub-Saharan African countries.
* When referencing clinical data on RTS,S any statements should be prefaced by "In this study...", to make it clear that it is too early to make any general statement on the vaccine profile outside the context of the ongoing clinical trails.
* Have you found what you were looking for? If you have any suggestions for information which should be included in this tool please contact us at the following address: Carys Calvert at [carys.calvert@gsk.com](mailto:carys.calvert@gsk.com).

Will RTS,S be available outside of sub-Saharan Africa?

Five different species of Plasmodium parasites cause malaria in different regions of the world. *Plasmodium falciparum*, which is targeted by the RTS,S malaria vaccine candidate, is considered to be the most deadly malaria parasite, and is the predominant species causing malaria in sub-Saharan Africa.

The vast majority of estimated cases (80%) and deaths (90%) occur in sub-Saharan Africa. The great majority of malaria deaths caused by the *Pf* parasite occur in children under the age of five (77%). Therefore the current priority is to make RTS,S available in this population as soon as possible.

In Asia and many parts of Latin America, *Plasmodium vivax* (*Pv*) is prevalent, although *Pf* is present with some hot spots. The impact of the RTS,S malaria vaccine candidate on clinical malaria outside Africa could therefore be more limited and would require further investigation. The potential age- and geographic extensions of RTS,S are still under discussion and would also require external funding.